ReviewCurrent neurology and neuroscience reports2012
An update on monoclonal gammopathy and neuropathy.
Review in Current neurology and neuroscience reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 74 citations in OpenAlex.
- Management and long-term haematological and neurological outcomes of Immunoglobulin M and Waldenström's macroglobulinaemia-related neuropathy: A single-centre experience.British journal of haematology · 2026Article
- Association of co-existing vitamin B6 and B12 deficiency with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome: a case report.BMC neurology · 2025Article
- CSF oligoclonal bands in neurological diseases besides CNS inflammatory demyelinating disorders.BMJ neurology open · 2025Article
- Role of tubulin post-translational modifications in peripheral neuropathy.Experimental neurology · 2023Review
- Case report: POEMS syndrome masquerades as diabetic foot.Frontiers in neurology · 2023Article
- Revisiting the spectrum of IgM-related neuropathies in a large cohort of IgM monoclonal gammopathy.Journal of neurology · 2022Article
- Corneal Densitometry and In Vivo Confocal Microscopy in Patients with Monoclonal Gammopathy-Analysis of 130 Eyes of 65 Subjects.Journal of clinical medicine · 2022Article
- Immune subtraction for improved resolution in serum protein immunofixation electrophoresis and antibody isotype determination in a patient with autoantibody.Practical laboratory medicine · 2021Article
- Article
- IgM paraprotein and anti-MAG sensory polyneuropathy associated with Waldenstrom's macroglobulinaemia and medullary carcinoma of the thyroid.BMJ case reports · 2021Article
- Ocular Signs and Ocular Comorbidities in Monoclonal Gammopathy: Analysis of 80 Subjects.Journal of ophthalmology · 2021Article
- Immunoglobulin M Paraproteinaemias.Cancers · 2020Review
- Supportive Care in Multiple Myeloma.Current hematologic malignancy reports · 2020Review
- Distinctive patterns of peripheral neuropathy across the spectrum of plasma cell disorders.Scientific reports · 2019Article
- Waldenstrom-associated anti-MAG paraprotein polyneuropathy with neurogenic tremor.BMJ case reports · 2019Article
- Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.Integrative cancer therapies · 2018Article
- What is the significance of monoclonal gammopathy of undetermined significance?Clinical medicine (London, England) · 2018Review
- Associated conditions in small fiber neuropathy - a large cohort study and review of the literature.European journal of neurology · 2018Review
- Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.Mayo Clinic proceedings · 2017Review
- Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral neuropathy associated with monoclonal gammopathy is a rare but important cause of neuropathy that can herald serious underlying disease. IgM monoclonal gammopathy of undetermined significance (MGUS) is the most commonly found monoclonal gammopathy associated with neuropathy, with characteristic clinical, electrophysiologic, and pathologic features. The IgG and IgA monoclonal gammopathies are rarely associated with specific neuropathies. Standard immunomodulatory agents including steroids, intravenous immunoglobulin, and plasmapheresis have shown limited efficacy in IgM MGUS. Neuropathies associated with specific lymphoproliferative disorders may not respond to treatments aimed at that disorder. Case series had shown promising results with rituximab, a monoclonal antibody that targets the B cell surface antigen CD20 and results in a rapid and sustained depletion of B cells; however, two recent randomized controlled trials with rituximab failed to provide evidence of efficacy in primary outcome measures, despite reduction in antibody levels. Long-term studies looking at the association between specific immunologic markers and disease recurrence are needed to ultimately develop targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.